Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 15;12(4):e220400.
doi: 10.1530/EC-22-0400. Print 2023 Apr 1.

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia

Annelies Van't Westeinde  1 , Leif Karlsson  1 , Valeria Messina  1 , Lena Wallensteen  1 , Manuela Brösamle  2 , Giorgio Dal Maso  3 , Alessandro Lazzerini  4 , Jette Kristensen  5 , Diana Kwast  6 , Lea Tschaidse  7 , Matthias K Auer  7 , Hanna F Nowotny  7 , Luca Persani  8   9 , Nicole Reisch  7 , Svetlana Lajic  1
Affiliations
Review

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia

Annelies Van't Westeinde et al. Endocr Connect. .

Abstract

First-trimester prenatal treatment with glucocorticoid (GC) dexamethasone (DEX) in pregnancies at risk for classic congenital adrenal hyperplasia (CAH) is associated with ethical dilemmas. Though effective in reducing virilisation in girls with CAH, it entails exposure to high doses of GC in fetuses that do not benefit from the treatment. The current paper provides an update on the literature on outcomes of prenatal DEX treatment in CAH cases and unaffected subjects. Long-term follow-up research is still needed to determine treatment safety. In addition, advances in early prenatal diagnostics for CAH and sex-typing as well as studies assessing dosing effects of DEX may avoid unnecessary treatment and improve treatment safety.

Keywords: CAH; brain development; dexamethasone; first trimester; prenatal treatment; treatment safety.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Figure 1
Figure 1
Overview of the prenatal dexamethasone treatment in pregnancies at risk for CAH. SRY analysis from maternal blood determines the sex of the fetus prior to DEX treatment. Treatment is only started if the fetus is a girl. Novel tests using whole genome sequencing (WGS) of fetal DNA obtained from maternal blood may in the future limit treatment to girls with CAH (yellow arrow). Currently, genotyping for CYP21A2 from chorionic villus sampling (CVS) is done at week 12, which determines the CAH diagnosis. DEX treatment is stopped in the case of an unaffected girl and continued until term in the case of a girl with CAH. If untreated, genitalia develop towards the male phenotype, as indicated on the right side of the figure.
Figure 2
Figure 2
Potential points of interference (left) and potential clinical consequences (right) of prenatal dexamethasone exposure. Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/).
Figure 3
Figure 3
Major steps of prenatal brain development that may be impacted by prenatal dexamethasone exposure. The yellow boxes indicate the start of DEX treatment at GW6–7 and the genotyping for CAH at GW12. Light-blue boxes indicate major events in prenatal brain development. *Although treatment currently is limited to girls because of the possibility of sex-typing prior to treatment, there are large cohorts that have received treatment before the SRY method was available and therefore contain both affected and unaffected boys. GW, gestational week.
See this image and copyright information in PMC

References

    1. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. American Journal of Human Genetics 198537 650–667. (10.1097/00006254-198604000-00017) - DOI - PMC - PubMed
    1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews 200021245–291. (10.1210/edrv.21.3.0398) - DOI - PubMed
    1. Wedell A.. Molecular genetics of 21-hydroxylase deficiency. Endocrine Development 20112080–87. (10.1159/000321223) - DOI - PubMed
    1. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BBMet al.Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocrine Reviews 20224391–159. (10.1210/endrev/bnab016) - DOI - PMC - PubMed
    1. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Murad MH, Oberfield SEet al.Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 20181034043–4088. (10.1210/jc.2018-01865) - DOI - PMC - PubMed